Name: Rare Kidney Diseases Market Size & Trends 2040
Creator: Roots Analysis
Published: 2026-08-03T00:00:01+05:30
License: https://www.rootsanalysis.com/privacy.html
Keywords: Rare Kidney Diseases Market, Rare Kidney Diseases Market Growth, Rare Kidney Diseases Market Trends, Rare Kidney Diseases Market Size, Rare Kidney Diseases Market Share, Rare Kidney Diseases Market Analysis, Rare Kidney Diseases Market Forecast, Rare Kidney Diseases Market Report, Global Rare Kidney Diseases Market, Rare Kidney Diseases Industry

Market Size

The global rare kidney diseases market size, valued at USD 3.4 billion in 2025, is projected to reach USD 4.9 billion in 2026 and USD 21.7 billion by 2040, with a CAGR of 11.2% during the forecast period 2026 to 2040.

Rare Kidney Disease Market Growth 2025 to 2040

See What’s in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

In terms of target indication, immunoglobulin A nephropathy holds majority of the current rare kidney diseases market, driven by rising disease prevalence, the approval of targeted therapies, and strong clinical trial activity in the domain.
Small molecules capture the largest share (more than 60%) of the overall rare kidney diseases market, owing to their proven efficacy along with their ease of administration, lower production costs and established safe drug profiles.
In terms of type of biologic, monoclonal antibodies capture the largest share of the current rare kidney diseases market as a result of the high target specificity and proven precision to treat rare kidney indications.
The oral route of administration currently captures the largest share (nearly 65%) of the rare kidney diseases market due to its non-invasive nature, convenience of drug administration and increased patient compliance.
In terms of type of therapy, monotherapies occupy a greater share of the rare kidney diseases market. Recent studies, though, have shown that combination therapies can be an effective alternative in patients with chronic kidney disease for whom other therapies are not effective.
North America holds nearly 60% of the rare kidney diseases market value. The market in Asia-Pacific is likely to grow at a relatively faster pace during the forecast period.

Rare Kidney Disease Market Size by Type of Molecule, 2026 and 2040

Your Business is Unique – Why Shouldn’t Your Report Be?

Key Market Statistics

Market Size in 2026: $4.9 Billion
Estimated Market Size in 2040: $21.7 Billion
CAGR (2026-2040): 11.2%
North America: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Overview

Kidney diseases are a set of conditions that hinder the kidney’s natural ability to efficiently filter fluid and waste from the blood. These diseases also lower the ability of the kidneys to regulate blood pressure and maintain overall fluid balance in the body. In the early stages, these diseases often do not reflect any symptoms, hence making it difficult to diagnose. As waste builds up in the body, patients may report symptoms, such as high blood pressure, anemia, poor nutritional health and nerve damage.

According to the US Chronic Kidney Disease Surveillance program, about 37 million people in the US are estimated to be suffering from chronic kidney disease, accounting for approximately 14% of the overall population in the US. Rare kidney diseases are a subset of kidney diseases, which affect only a small fraction of people worldwide. According to the Orphan Drug Act, in the United States, diseases are considered rare when they affect less than 200,000 Americans. However, according to the European Union, the prevalence threshold is 5 per 10,000 people., ,

These diseases primarily affect the filtering units (known as glomeruli), present in the kidneys, which result in the spillage of protein components and blood into the urine. Considering that these diseases can either be congenital, acquired or inherited in nature, it is highly difficult to identify biomarkers for their diagnosis and treatment. If these conditions do not receive timely treatment, they ultimately result in kidney failure and can, subsequently, only be managed through dialysis and kidney transplantation. Kidney failure due to a rare chronic kidney disease has been observed to be prevalent in at least 3 in 5 children and 1 in 9 adults suffering from kidney diseases. This growing burden of rare kidney disorders is prompting industry stakeholders, including pharmaceutical companies and biotech firms, to accelerate the development of targeted therapies and orphan drugs specifically designed to address these underserved conditions. Across related applications, complement inhibitors block dysregulated complement activation implicated in neurological, hematological and renal diseases.

Recent Developments

In June 2026, AstraZeneca received Priority Review designation by the US FDA for its drug Ultomiris (Ravulizumab), indicated for the treatment of Immunoglobulin A Nephropathy.
In June 2026, Ascidian Therapeutics announced a licensing agreement with Eli Lilly worth up to $1.9 Billion, for developing therapies for rare inherited kidney diseases. Under this agreement, Lilly agreed to use Ascidian’s RNA exon editing technology for selected kidney disease targets.
In June 2026, Travere Therapeutics signed a licensing agreement with Everest Medicines for expanding its rare kidney disease pipeline. Under this agreement, Travere received the rights for commercialization of civorebrutinib (a potential best in class BTK inhibitor) outside China and parts of East and Southeast Asia.
In April 2026, Travere announced that the US FDA has granted approval to its drug, Filspari, for the treatment of focal segmental glomerulosclerosis. This marks a historic milestone for patients living with this condition.
In April 2026, Climb Bio received Fast Track designation by the US FDA for its drug candidate budoprutug, indicated for the treatment of primary membranous nephropathy. The drug has demonstrated the ability to induce deep and sustained B-cell depletion, reduce antibody levels and drive clinical remission in early studies.

Rare Kidney Diseases Market Trends

Partnerships and Collaborations: Several rare kidney disease companies have recently pursued partnerships to strengthen their market position. Product licensing emerged as the most prominent partnership model, closely followed by acquisitions. Companies undertake such collaborations to rapidly expand clinical and commercial capabilities, lower development risks, and bypass heavy internal investment. Through these alliances, they immediately access their partners’ regulatory expertise, manufacturing capacity, and established market channels.
Clinical Trials Analysis: Since 2020, researchers have launched or completed nearly 405 clinical trials for rare kidney diseases, signaling strong industry momentum. Interestingly, over 30% of these trials were registered in 2025, reflecting surging interest among researchers and drug developers in the development of novel therapies. Asia-Pacific currently leads the clinical trial landscape, hosting majority of the ongoing and completed trials.

Scope, Methodology and Industry Experts Interviews

Roots Analysis segments the rare kidney diseases by target indication, type of molecule, type of biologic, route of administration, type of therapy, geographical regions, and leading drug developers.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders across the rare kidney diseases domain. These discussions informed the assessment of disease diagnosis and treatment pathways, unmet clinical needs, drug development activity, patient identification and recruitment challenges, treatment adoption, partnership activity, funding, regulatory considerations, reimbursement dynamics, and commercial opportunities. The market report includes detailed transcripts of the following third-party discussions:

Founder and Chief Executive Officer, Mid-Sized Company, US
President and Chief Executive Officer, Mid-Sized Company, US
President and Chief Executive Officer, Mid-Sized Company, Israel
Executive Director, Strategic Relations, Small Sized Non-Profit Organization, US
Associate BD Director, Very Large Company, China
Nephrologist, Very Large Clinic, UK; Nephrologist, Large Hospital, UK
Nephrologist, Medical Director, Mid-Sized Company, United States; Professor of Medicine, Very Large University, US; Associate Professor, Very Large University, US
Professor of Nephrology and Chair of Nephrology, Very Large University, US
Professor of Medicine, Very Large University, Belgium

Commenting on this Chris Gisler, Nephrologist, Medical Director, Travere Therapeutics states, “The future of rare kidney disease treatment paradigm is likely to involve multi-pathway treatment strategies. Moreover, combination therapies targeting different biological mechanisms may provide greater disease control than single-therapy options.”

Pay Only for What You Need – The Best Way to Optimize

Market Drivers

Rising Incentives by Regulatory Agencies: Regulatory incentives such as Orphan Drug and Fast-Track designations are accelerating market entry for rare kidney disease therapies by shortening development timelines, enabling priority review, and offering extended market exclusivity. These designations reduce investment risk, attract the interest of biopharmaceutical companies, and encourage strategic partnerships, collectively driving innovation, commercial viability, and faster patient access in the rare kidney diseases market.
Advances in Biomarker Discovery and Genetic Screening: Advances in genetic testing and biomarker discovery are improving detection of inherited kidney disorders (such as Fabry disease), enabling earlier and more accurate diagnoses. Timely identification accelerates patient enrollment in clinical trials, facilitates personalized treatment strategies, and supports targeted drug development. Together, these trends increase demand for specialized therapies and expand market opportunities in the rare kidney disease industry.

Market Segmentation Analysis

Immunoglobulin A Nephropathy Leading the Rare Kidney Diseases Market

Immunoglobulin A nephropathy holds nearly 40% of the overall rare kidney diseases market share and is likely to remain dominant during the forecast period. This is a result of the increasing incidence and improved diagnosis rates of the disease, along with the availability of newly approved targeted therapies and a strong pipeline of ongoing clinical trials. Governments and healthcare providers are also placing greater emphasis on early intervention for immunoglobulin A nephropathy to mitigate the substantial long-term economic burden associated with dialysis and kidney transplants, further driving investment and development in this area.

Oral Route is Driving the Rare Kidney Diseases Market

The oral route segment currently holds nearly 65% of the market share, owing to the ease of self-administration, lower treatment costs, better suitability for long-term chronic therapy, and better patient adherence. The rare kidney diseases market for subcutaneous route of administration nonetheless is likely to grow at a higher CAGR of 19%, owing to the various associated benefits including patient preference and convenience.

Rare Kidney Disease Market Outlook by Route of Administration, 2040

Market Regional Insights

North America Dominates the Overall Market

North America dominates the market for rare kidney diseases, securing nearly 60% of the overall revenue share, due to strong research and development, high concentration of biotechnology companies, and a favorable regulatory environment for orphan drugs in the US. These factors support pharmaceutical drug development pipelines and accelerate commercialization as compared to other regions.

Asia-Pacific to See Market Expansion

Asia-Pacific is playing a pivotal role in accelerating the rare kidney diseases market through stronger research collaboration, rising healthcare investment, and faster recognition of unmet patient needs. Regional initiatives are also improving diagnosis, specialist coordination, and access to emerging therapies, which is helping translate scientific progress into market expansion.

Emerging Opportunities in Rare Kidney Diseases Market

Precision Combination Therapies for Rare Kidney Diseases Guided by Molecular Profiling

Combination therapies and personalized medicine are converging to create a transformative opportunity in the rare kidney disease drug market, as targeted combination regimens enable simultaneous modulation of multiple disease pathways while individualized molecular profiling helps optimize therapeutic selection and dosing for each patient. By integrating genomic (genes), protein, and clinical biomarkers, developers can effectively identify patients within diverse patient populations, reduce trial sizes, and accelerate regulatory acceptance through better benefit signals. Payers and health systems are increasingly recognizing the long-term value of precision approaches, which help lower long-term morbidity and healthcare costs. This recognition is driving greater investment, collaborative trials, and adaptation of regulatory pathways, collectively de-risking development and accelerating patient access to novel kidney therapies.

AI-Driven Drug Discovery and Development for Rare Kidney Diseases Market

Artificial intelligence is transforming the rare kidney diseases market by accelerating the identification and development of new therapeutic candidates. Pharmaceutical companies actively leverage AI-powered platforms to analyze complex biological data, uncover novel disease pathways, and predict potential drug candidates with higher precision. This technology significantly shortens the traditional drug discovery timeline and reduces development costs. As a result, companies can bring innovative treatments for rare kidney conditions to market more rapidly while improving the overall success rate of clinical pipelines.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Rare Kidney Diseases Market: Scope of the Report

Key Report Attributes	Details
Segments Covered	Target Indication, Type of Molecule, Type of Biologic, Route of Administration, Type of Therapy, Geographical Regions, and Leading Drug Developers
Excel Data Packs (Complimentary)	Market Landscape, Company Competitiveness Analysis, Partnerships and Collaborations, Funding and Investments, Clinical Trial Analysis, Clinical Commercial Attractiveness, Key Opinion Leaders Analysis, Market Forecast and Opportunity Analysis, and Leading Drug Developers
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Market Segments

Based on the research, we have segmented the Rare Kidney Diseases Market into target indication, type of molecule, type of biologic, route of administration, type of therapy, and geographical regions.

By Target Indication

Immunoglobulin A Nephropathy, Lupus Nephritis, Atypical Hemolytic Uremic Syndrome, Fabry Disease, Focal Segmental Glomerulosclerosis, Complement 3 Glomerulopathy, Hepatorenal Syndrome, Immune Complex-Mediated Membranoproliferative Glomerulonephritis, Distal Renal Tubular Acidosis, Membranous Nephropathy, and Nephrotic Syndrome

By Type of Molecule

Small Molecules and Biologics

By Type of Biologic

Monoclonal Antibodies, Enzymes, Proteins / Peptides, Hormones, and Cell / Gene Therapies

By Route of Administration

Oral Route, Intravenous Route, and Subcutaneous Route

By Type of Therapy

Monotherapies and Combination Therapies

By Geographical Regions

North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa

By Leading Drug Developers

Key Players

The report profiles Advicenne, Alexion Pharmaceuticals, Amgen, Asahi Kasei, Biogen, Boehringer Ingelheim, Calliditas Therapeutics, Jiangsu Hengrui Pharmaceuticals, Novartis, NovelMed, Roche, Travere Therapeutics, Vertex Pharmaceuticals, Vera Therapeutics, and ZyVersa Therapeutics.

Report Authorship

This report was authored by Simriti Gupta, member of Roots Analysis healthcare and pharmaceutical research practice. Her work focuses on drug development and manufacturing, competitive intelligence, company benchmarking and market forecasting.

Independence and Non-Affiliation

Roots Analysis is an independent secondary and primary market research publisher. This report is not affiliated with, endorsed by, or produced on behalf of any company named or profiled within it, including all key players and industry expert interviewees referenced above.

Roots Analysis' findings draw on a combination of secondary research and primary interviews with industry experts, of the kind referenced above, to validate market sizing, segment shares, and forecast assumptions independently of any single company's disclosures.

+ 1. BACKGROUND

1.1. Context

1.2. Project Objectives

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends (since 2023)

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russia-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Overview of Kidney Diseases

6.1.1. Key Historical Events Related to Kidney Diseases

6.1.2. Factors Contributing to the Onset of Kidney Diseases

6.2. Selection of Therapeutic Targets for Rare Kidney Diseases

6.3. Technological Advancements in the Rare Kidney Diseases Domain

6.4. Recent Developments in the Rare Kidney Diseases Domain

6.5. Future Perspectives

+ 7. MARKET LANDSCAPE

7.1. Rare Kidney Disease Drugs / Therapies: Market Landscape

7.1.1. Analysis by Stage of Development

7.1.2. Analysis by Target Indication

7.1.3. Analysis by Route of Administration

7.1.4. Analysis by Type of Molecule

7.1.5. Analysis by Type of Biologic

7.1.6. Analysis by Dosing Frequency

7.1.7. Analysis by Target Patient Population

7.1.8. Analysis by Type of Therapy

7.2. Rare Kidney Disease Drugs / Therapies: Developer Landscape

7.2.1. Analysis by Year of Establishment

7.2.2. Analysis by Company Size

7.2.3. Analysis by Location of Headquarters

7.2.4. Analysis by Company Size and Location of Headquarters

7.2.5. Most Active Players: Analysis by Number of Drugs / Therapies Developed

+ 8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Methodology and Key Parameters

8.2. Scoring

8.3. Peer Groups

8.3.1. Overview of Developers based in North America

8.3.1.1. Competitiveness Analysis of Players based in North America

8.3.1.2. Leading Players based in North America

8.3.2. Overview of Developers based in Europe

8.3.2.1. Competitiveness Analysis of Players based in Europe

8.3.2.2. Leading Players based in Europe

8.3.3. Overview of Developers based in Asia-Pacific and Rest of the World

8.3.3.1. Competitiveness Analysis of Players based in Asia-Pacific and Rest of the World

8.3.3.2. Leading Players based in Asia-Pacific and Rest of the World

+ 9. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY

9.1. Chapter Overview

9.2. Rare Kidney Disease Drug Developers

9.2.1. SanegeneBio

9.2.1.1. Company Details

9.2.1.2. Drug Portfolio

9.2.1.3. Recent Developments and Future Outlook

9.2.2. Alexion

9.2.2.1. Company Details

9.2.2.2. Drug Portfolio

9.2.2.3. Financial Details

9.2.2.4. Recent Developments and Future Outlook

9.2.3. Vertex Pharmaceuticals

9.2.3.1. Company Details

9.2.3.2. Drug Portfolio

9.2.3.3. Financial Details

9.2.3.4. Recent Developments and Future Outlook

9.2.4. Novartis

9.2.4.1. Company Details

9.2.4.2. Drug Portfolio

9.2.4.3. Financial Details

9.2.4.4. Recent Developments and Future Outlook

9.2.5. Roche

9.2.5.1. Company Details

9.2.5.2. Drug Portfolio

9.2.5.3. Financial Details

9.2.5.4. Recent Developments and Future Outlook

9.2.6. Jiangsu Hengrui Pharmaceuticals

9.2.6.1. Company Details

9.2.6.2. Drug Portfolio

9.2.6.3. Financial Details

9.2.6.4. Recent Developments and Future Outlook

9.3. Other Leading Developers

9.3.1. Biogen

9.3.2. Travere Therapeutics

9.3.3. Amgen

9.3.4. NovelMed

9.3.5. Vera Therapeutics

9.3.6. ZyVersa Therapeutics

9.3.7. Advicenne

9.3.8. Boehringer Ingelheim

9.3.9. Calliditas

9.3.10. Asahi Kasei

+ 10. PARTNERSHIPS AND COLLABORATIONS

10.1. Partnership Models

10.2. Rare Kidney Disease Drugs / Therapies: Partnerships and Collaborations

10.2.1. Analysis by Year of Partnership

10.2.2. Analysis by Type of Partnership

10.2.3. Analysis by Year and Type of Partnership

10.2.4. Analysis by Target Indication

10.2.5. Analysis by Type of Partner

10.2.6. Most Active Players: Analysis by Number of Partnerships

10.2.7. Local and International Deals

10.2.8. Intercontinental and Intracontinental Deals

+ 11. FUNDING AND INVESTMENTS

11.1. Funding Models

11.2. Funding Lifecycle Analysis

11.3. Investment Case: Risk and Return

11.4. Rare Kidney Disease Drugs / Therapies: Funding and Investments

11.4.1. Analysis of Funding Instances by Year of Funding

11.4.2. Analysis of Funding Instances by Type of Funding

11.4.3. Analysis of Funding Instances by Year and Type of Funding

11.4.4. Analysis of Amount Invested by Year of Funding

11.4.5. Analysis of Amount Invested by Type of Funding

11.4.6. Analysis of Amount Invested by Year and Type of Funding

11.4.7. Analysis of Funding Instances by Target Indication

11.4.8. Analysis of Funding Instances by Geography (Region)

11.4.9. Analysis of Funding Instances by Geography (Country)

11.4.10. Most Active Players: Analysis by Number of Funding Instances

11.4.11. Most Active Players: Analysis by Amount Invested

11.4.12. Leading Investors: Analysis by Number of Funding Instances

11.5. Summary of Investments

+ 12. CLINICAL TRIAL ANALYSIS

12.1. Methodology and Key Parameters

12.2. Rare Kidney Disease Drugs / Therapies: Clinical Trial Analysis

12.2.1. Analysis by Trial Registration Year

12.2.2. Analysis by Trial Status

12.2.3. Analysis by Trial Registration Year and Trial Status

12.2.4. Analysis by Trial Registration Year and Patients Enrolled

12.2.5. Analysis by Trial Status and Patients Enrolled

12.2.6. Analysis by Trial Phase

12.2.7. Analysis by Patients Enrolled and Trial Phase

12.2.8. Analysis by Study Design

12.2.9. Analysis by Type of Sponsor

12.2.10. Analysis by Patient Gender

12.2.11. Most Active Industry Players: Analysis by Number of Trials

12.2.12. Most Active Non-Industry Players: Analysis by Number of Trials

12.2.13. Analysis by Geography

12.2.13.1. Analysis by Trial Status, Trial Phase and Geography

12.2.13.2. Analysis by Trial Status and Geography

12.2.14. Analysis of Trials and Number of Patients Enrolled by Geography

12.2.14.1. Clinical Trials in North America: Key Insights

12.2.14.2. Clinical Trials in Europe: Key Insights

12.2.14.3. Clinical Trials in Asia-Pacific: Key Insights

12.2.14.4. Clinical Trials in Rest of the World: Key Insights

+ 13. CLINICAL COMMERCIAL ATTRACTIVENESS

13.1. Methodology and Key Parameters

13.2. Scoring

13.3. Phase III Drugs / Therapies Targeting Rare Kidney Diseases: 4D Bubble Chart

+ 14. KEY OPINION LEADERS

14.1. Methodology and Key Parameters

14.2. Rare Kidney Disease Drugs / Therapies: Key Opinion Leaders

14.2.1. Analysis by Type of Key Opinion Leader

14.2.2. Analysis by Qualification

14.2.3. Analysis by Type of Organization

14.2.4. Analysis by Target Indication

14.2.5. Analysis by Region of Key Opinion Leaders

14.3. Scoring Criteria

14.3.1. Most Prominent Key Opinion Leaders

14.3.2. Benchmarking: Roots Analysis’ Assessment vs Third Party Scores

+ 15. CASE STUDY ON KIDNEY CARE COMPANIES

15.1. Methodology

15.2. Rare Kidney Disease Market: List of Kidney Care Companies

15.3. Benefits Offered by Kidney Care Companies

15.4. Recent Developments

+ 16. MARKET IMPACT ANALYSIS

16.1. Chapter Overview

16.2. Market Drivers

16.3. Market Restraints

16.4. Market Opportunities

16.5. Market Challenges

+ 17. RARE KIDNEY DISEASE MARKET

17.1. Key Assumptions and Methodology

17.2. Global Rare Kidney Disease Market: Historical Trends (since 2023) and Forecasted Estimates, till 2040

17.2.1. Comparison with Previous Edition

17.2.2. Multivariate Scenario Analysis

17.2.2.1. Conservative Scenario

17.2.2.2. Optimistic Scenario

17.3. Key Market Segmentations

+ 18. RARE KIDNEY DISEASE MARKET, BY TARGET INDICATION

18.1. Rare Kidney Disease Market: Distribution by Target Indication

18.1.1. Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

18.1.2. Rare Kidney Disease Market for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

18.1.3. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

18.1.4. Rare Kidney Disease Market for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040

18.1.5. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040

18.1.6. Rare Kidney Disease Market for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040

18.1.7. Rare Kidney Disease Market for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

18.1.8. Rare Kidney Disease Market for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040

18.1.9. Rare Kidney Disease Market for Distal Renal Tubular Acidosis: Forecasted Estimates, till 2040

18.1.10. Rare Kidney Disease Market for Membranous Nephropathy: Forecasted Estimates, till 2040

18.1.11. Rare Kidney Disease Market for Nephrotic Syndrome: Forecasted Estimates, till 2040

+ 19. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE

19.1. Rare Kidney Disease Market: Distribution by Type of Molecule

19.1.1. Rare Kidney Disease Market for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040

19.1.2. Rare Kidney Disease Market for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 20. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGIC

20.1. Rare Kidney Disease Market: Distribution by Type of Biologic

20.1.1. Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

20.1.2. Rare Kidney Disease Market for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040

20.1.3. Rare Kidney Disease Market for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040

20.1.4. Rare Kidney Disease Market for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040

20.1.5. Rare Kidney Disease Market for Cell and Gene Therapies: Forecasted Estimates, till 2040

+ 21. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION

21.1. Rare Kidney Disease Market: Distribution by Route of Administration

21.1.1. Rare Kidney Disease Market for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

21.1.2. Rare Kidney Disease Market for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

21.1.3. Rare Kidney Disease Market for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 22. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY

22.1. Rare Kidney Disease Market: Distribution by Type of Therapy

22.1.1. Rare Kidney Disease Market for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

22.1.2. Rare Kidney Disease Market for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 23. RARE KIDNEY DISEASE MARKET, BY GEOGRAPHICAL REGIONS

23.1. Rare Kidney Disease Market: Distribution by Geographical Regions

23.1.1. Rare Kidney Disease Market in North America: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.1.1. Rare Kidney Disease Market in the United States: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.1.2. Rare Kidney Disease Market in Canada: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2. Rare Kidney Disease Market in Europe: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2.1. Rare Kidney Disease Market in Germany: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2.2. Rare Kidney Disease Market in United Kingdom: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2.3. Rare Kidney Disease Market in France: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2.4. Rare Kidney Disease Market in Spain: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2.5. Rare Kidney Disease Market in Italy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.2.6. Rare Kidney Disease Market in Rest of Europe: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3. Rare Kidney Disease Market in Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3.1. Rare Kidney Disease Market in China: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3.2. Rare Kidney Disease Market in Japan: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3.3. Rare Kidney Disease Market in Australia: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3.4. Rare Kidney Disease Market in India: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3.5. Rare Kidney Disease Market in South Korea: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.3.6. Rare Kidney Disease Market in Rest of Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.4. Rare Kidney Disease Market in Latin America: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.4.1. Rare Kidney Disease Market in Brazil: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.4.2. Rare Kidney Disease Market in Mexico: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.4.3. Rare Kidney Disease Market in Argentina: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.5. Rare Kidney Disease Market in Middle East and Africa: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.5.1. Rare Kidney Disease Market in Saudi Arabia: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.5.2. Rare Kidney Disease Market in Israel: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.5.3. Rare Kidney Disease Market in United Arab Emirates: Historical Trends (since 2023) and Forecasted Estimates, till 2040

23.1.5.4. Rare Kidney Disease Market in Egypt: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 24. RARE KIDNEY DISEASE MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA**

24.1. Rare Kidney Disease Market in North America: Distribution by Target Indication

24.1.1. Rare Kidney Disease Market in North America for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.1.2. Rare Kidney Disease Market in North America for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.1.3. Rare Kidney Disease Market in North America for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.1.4. Rare Kidney Disease Market in North America for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.1.5. Rare Kidney Disease Market in North America for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040

24.1.6. Rare Kidney Disease Market in North America for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040

24.1.7. Rare Kidney Disease Market in North America for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.1.8. Rare Kidney Disease Market in North America for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040

24.1.9. Rare Kidney Disease Market in North America for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.1.10. Rare Kidney Disease Market in North America for Membranous Nephropathy: Forecasted Estimates, till 2040

24.1.11. Rare Kidney Disease Market in North America for Nephrotic Syndrome: Forecasted Estimates, till 2040

24.2. Rare Kidney Disease Market in North America: Distribution by Type of Molecule

24.2.1. Rare Kidney Disease Market in North America for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.2.2. Rare Kidney Disease Market in North America for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.3. Rare Kidney Disease Market in North America: Distribution by Type of Biologic

24.3.1. Rare Kidney Disease Market in North America for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.3.2. Rare Kidney Disease Market in North America for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.3.3. Rare Kidney Disease Market in North America for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040

24.3.4. Rare Kidney Disease Market in North America for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.3.5. Rare Kidney Disease Market in North America for Cell and Gene Therapies: Forecasted Estimates, till 2040

24.4. Rare Kidney Disease Market in North America: Distribution by Route of Administration

24.4.1. Rare Kidney Disease Market in North America for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.4.2. Rare Kidney Disease Market in North America for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.4.3. Rare Kidney Disease Market in North America for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.5. Rare Kidney Disease Market in North America: Distribution by Type of Therapy

24.5.1. Rare Kidney Disease Market in North America for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

24.5.2. Rare Kidney Disease Market in North America for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 25. RARE KIDNEY DISEASE MARKET OPPORTUNITY ANALYSIS: EUROPE**

25.1. Rare Kidney Disease Market in Europe: Distribution by Target Indication

25.1.1. Rare Kidney Disease Market in Europe for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.1.2. Rare Kidney Disease Market in Europe for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.1.3. Rare Kidney Disease Market in Europe for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.1.4. Rare Kidney Disease Market in Europe for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.1.5. Rare Kidney Disease Market in Europe for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040

25.1.6. Rare Kidney Disease Market in Europe for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040

25.1.7. Rare Kidney Disease Market in Europe for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.1.8. Rare Kidney Disease Market in Europe for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040

25.1.9. Rare Kidney Disease Market in Europe for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.1.10. Rare Kidney Disease Market in Europe for Membranous Nephropathy: Forecasted Estimates, till 2040

25.1.11. Rare Kidney Disease Market in Europe for Nephrotic Syndrome: Forecasted Estimates, till 2040

25.2. Rare Kidney Disease Market in Europe: Distribution by Type of Molecule

25.2.1. Rare Kidney Disease Market in Europe for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.2.2. Rare Kidney Disease Market in Europe for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.3. Rare Kidney Disease Market in Europe: Distribution by Type of Biologic

25.3.1. Rare Kidney Disease Market in Europe for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.3.2. Rare Kidney Disease Market in Europe for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.3.3. Rare Kidney Disease Market in Europe for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040

25.3.4. Rare Kidney Disease Market in Europe for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.3.5. Rare Kidney Disease Market in Europe for Cell and Gene Therapies: Forecasted Estimates, till 2040

25.4. Rare Kidney Disease Market in Europe: Distribution by Route of Administration

25.4.1. Rare Kidney Disease Market in Europe for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.4.2. Rare Kidney Disease Market in Europe for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.4.3. Rare Kidney Disease Market in Europe for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.5. Rare Kidney Disease Market in Europe: Distribution by Type of Therapy

25.5.1. Rare Kidney Disease Market in Europe for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

25.5.2. Rare Kidney Disease Market in Europe for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 26. RARE KIDNEY DISEASE MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC**

26.1. Rare Kidney Disease Market in Asia-Pacific: Distribution by Target Indication

26.1.1. Rare Kidney Disease Market in Asia-Pacific for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.1.2. Rare Kidney Disease Market in Asia-Pacific for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.1.3. Rare Kidney Disease Market in Asia-Pacific for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.1.4. Rare Kidney Disease Market in Asia-Pacific for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.1.5. Rare Kidney Disease Market in Asia-Pacific for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040

26.1.6. Rare Kidney Disease Market in Asia-Pacific for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040

26.1.7. Rare Kidney Disease Market in Asia-Pacific for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.1.8. Rare Kidney Disease Market in Asia-Pacific for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040

26.1.9. Rare Kidney Disease Market in Asia-Pacific for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.1.10. Rare Kidney Disease Market in Asia-Pacific for Membranous Nephropathy: Forecasted Estimates, till 2040

26.1.11. Rare Kidney Disease Market in Asia-Pacific for Nephrotic Syndrome: Forecasted Estimates, till 2040

26.2. Rare Kidney Disease Market in Asia-Pacific: Distribution by Type of Molecule

26.2.1. Rare Kidney Disease Market in Asia-Pacific for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.2.2. Rare Kidney Disease Market in Asia-Pacific for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.3. Rare Kidney Disease Market in Asia-Pacific: Distribution by Type of Biologic

26.3.1. Rare Kidney Disease Market in Asia-Pacific for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.3.2. Rare Kidney Disease Market in Asia-Pacific for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.3.3. Rare Kidney Disease Market in Asia-Pacific for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040

26.3.4. Rare Kidney Disease Market in Asia-Pacific for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.3.5. Rare Kidney Disease Market in Asia-Pacific for Cell and Gene Therapies: Forecasted Estimates, till 2040

26.4. Rare Kidney Disease Market in Asia-Pacific: Distribution by Route of Administration

26.4.1. Rare Kidney Disease Market in Asia-Pacific for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.4.2. Rare Kidney Disease Market in Asia-Pacific for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.4.3. Rare Kidney Disease Market in Asia-Pacific for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.5. Rare Kidney Disease Market in Asia-Pacific: Distribution by Type of Therapy

26.5.1. Rare Kidney Disease Market in Asia-Pacific for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

26.5.2. Rare Kidney Disease Market in Asia-Pacific for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 27. RARE KIDNEY DISEASE MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA**

27.1. Rare Kidney Disease Market in Latin America: Distribution by Target Indication

27.1.1. Rare Kidney Disease Market in Latin America for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.1.2. Rare Kidney Disease Market in Latin America for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.1.3. Rare Kidney Disease Market in Latin America for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.1.4. Rare Kidney Disease Market in Latin America for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.1.5. Rare Kidney Disease Market in Latin America for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040

27.1.6. Rare Kidney Disease Market in Latin America for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040

27.1.7. Rare Kidney Disease Market in Latin America for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.1.8. Rare Kidney Disease Market in Latin America for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040

27.1.9. Rare Kidney Disease Market in Latin America for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.1.10. Rare Kidney Disease Market in Latin America for Membranous Nephropathy: Forecasted Estimates, till 2040

27.1.11. Rare Kidney Disease Market in Latin America for Nephrotic Syndrome: Forecasted Estimates, till 2040

27.2. Rare Kidney Disease Market in Latin America: Distribution by Type of Molecule

27.2.1. Rare Kidney Disease Market in Latin America for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.2.2. Rare Kidney Disease Market in Latin America for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.3. Rare Kidney Disease Market in Latin America: Distribution by Type of Biologic

27.3.1. Rare Kidney Disease Market in Latin America for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.3.2. Rare Kidney Disease Market in Latin America for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.3.3. Rare Kidney Disease Market in Latin America for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040

27.3.4. Rare Kidney Disease Market in Latin America for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.3.5. Rare Kidney Disease Market in Latin America for Cell and Gene Therapies: Forecasted Estimates, till 2040

27.4. Rare Kidney Disease Market in Latin America: Distribution by Route of Administration

27.4.1. Rare Kidney Disease Market in Latin America for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.4.2. Rare Kidney Disease Market in Latin America for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.4.3. Rare Kidney Disease Market in Latin America for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.5. Rare Kidney Disease Market in Latin America: Distribution by Type of Therapy

27.5.1. Rare Kidney Disease Market in Latin America for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

27.5.2. Rare Kidney Disease Market in Latin America for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

+ 28. RARE KIDNEY DISEASE MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND AFRICA**

28.1. Rare Kidney Disease Market in Middle East and Africa: Distribution by Target Indication

28.1.1. Rare Kidney Disease Market in Middle East and Africa for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.1.2. Rare Kidney Disease Market in Middle East and Africa for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.1.3. Rare Kidney Disease Market in Middle East and Africa for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.1.4. Rare Kidney Disease Market in Middle East and Africa for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.1.5. Rare Kidney Disease Market in Middle East and Africa for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040

28.1.6. Rare Kidney Disease Market in Middle East and Africa for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040

28.1.7. Rare Kidney Disease Market in Middle East and Africa for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.1.8. Rare Kidney Disease Market in Middle East and Africa for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040

28.1.9. Rare Kidney Disease Market in Middle East and Africa for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.1.10. Rare Kidney Disease Market in Middle East and Africa for Membranous Nephropathy: Forecasted Estimates, till 2040

28.1.11. Rare Kidney Disease Market in Middle East and Africa for Nephrotic Syndrome: Forecasted Estimates, till 2040

28.2. Rare Kidney Disease Market in Middle East and Africa: Distribution by Type of Molecule

28.2.1. Rare Kidney Disease Market in Middle East and Africa for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.2.2. Rare Kidney Disease Market in Middle East and Africa for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.3. Rare Kidney Disease Market in Middle East and Africa: Distribution by Type of Biologic

28.3.1. Rare Kidney Disease Market in Middle East and Africa for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.3.2. Rare Kidney Disease Market in Middle East and Africa for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.3.3. Rare Kidney Disease Market in Middle East and Africa for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040

28.3.4. Rare Kidney Disease Market in Middle East and Africa for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.3.5. Rare Kidney Disease Market in Middle East and Africa for Cell and Gene Therapies: Forecasted Estimates, till 2040

28.4. Rare Kidney Disease Market in Middle East and Africa: Distribution by Route of Administration

28.4.1. Rare Kidney Disease Market in Middle East and Africa for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.4.2. Rare Kidney Disease Market in Middle East and Africa for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.4.3. Rare Kidney Disease Market in Middle East and Africa for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.5. Rare Kidney Disease Market in Middle East and Africa: Distribution by Type of Therapy

28.5.1. Rare Kidney Disease Market in Middle East and Africa for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

28.5.2. Rare Kidney Disease Market in Middle East and Africa for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040

**Detailed segment-wise distribution across individual regions is available in supporting excel data packs

+ 29. RARE KIDNEY DISEASE MARKET, SALES FORECAST OF DRUGS

29.1. Approved Rare Kidney Disease Drugs / Therapies: Sales Forecast

29.1.1. ULTOMIRIS® (Atypical Hemolytic Uremic Syndrome): Sales Forecast

29.1.2. Tarpeyo® (Immunoglobulin A Nephropathy): Sales Forecast

29.1.3. Galafold (Fabry Disease): Sales Forecast

29.1.4. FILSPARI® (Immunoglobulin A Nephropathy): Sales Forecast

29.1.5. Benlysta® (Lupus Nephritis): Sales Forecast

29.1.6. Fabhalta (Immunoglobulin A Nephropathy): Sales Forecast

29.1.7. LUPKYNIS® (Lupus Nephritis): Sales Forecast

29.1.8. FILSPARI® (Focal Segmental Glomerulosclerosis): Sales Forecast

29.1.9. Voyxact (Immunoglobulin A Nephropathy): Sales Forecast

29.1.10. Elfabrio® (Fabry Disease): Sales Forecast

29.1.11. Vanrafia (Immunoglobulin A Nephropathy): Sales Forecast

29.1.12. Obinutuzumab (Lupus Nephritis): Sales Forecast

29.1.13. Fabhalta (Complement 3 Glomerulopathy): Sales Forecast

29.1.14. TERLIVAZ (Hepatorenal Syndrome): Sales Forecast

29.1.15. EMPAVELI (Complement 3 Glomerulopathy): Sales Forecast

29.1.16. EMPAVELI (Immune Complex-Mediated Membranoproliferative Glomerulonephritis): Sales Forecast

29.1.17. Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast

29.1.18. Sibnayal® (Distal Renal Tubular Acidosis): Sales Forecast

29.2. Phase III Rare Kidney Disease Drugs / Therapies: Sales Forecast

29.2.1. Sefaxersen (Immunoglobulin A Nephropathy): Sales Forecast

29.2.2. Atacicept (Immunoglobulin A Nephropathy): Sales Forecast

29.2.3. Obinutuzumab (Membranous Nephropathy): Sales Forecast

29.2.4. Obinutuzumab (Nephrotic Syndrome): Sales Forecast

29.2.5. Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast

29.2.6. INM004 (Atypical Hemolytic Uremic Syndrome): Sales Forecast

29.2.7. Venglustat (Fabry Disease): Sales Forecast

29.2.8. Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast

29.2.9. Fabhalta (Atypical Hemolytic Uremic Syndrome): Sales Forecast

29.2.10. ULTOMIRIS (Immunoglobulin A Nephropathy): Sales Forecast

29.2.11 SNP-ACTH (Membranous Nephropathy): Sales Forecast

29.2.12 Povetacicept (Immunoglobulin A Nephropathy): Sales Forecast

29.2.13. Mezagitamab (Immunoglobulin A Nephropathy): Sales Forecast

29.2.14. Ianalumab (Lupus Nephritis): Sales Forecast

29.2.15. Saphnelo (Lupus Nephritis): Sales Forecast

29.2.16. Felzartamab (Immunoglobulin A Nephropathy): Sales Forecast

29.2.17. Felzartamab (Membranous Nephropathy): Sales Forecast

29.2.18. Irbesartan (Focal Segmental Glomerulosclerosis): Sales Forecast

29.2.19 Lucerastat (Fabry Disease): Sales Forecast

29.2.20. Fabhalta (Immune Complex-Mediated Membranoproliferative Glomerulonephritis): Sales Forecast

29.2.21. BI 764198 (Focal Segmental Glomerulosclerosis): Sales Forecast

+ 30. RARE KIDNEY DISEASE MARKET, BY LEADING DRUG DEVELOPERS

+ 31. CONCLUDING INSIGHTS

+ 32. EXECUTIVE INSIGHTS

32.1. Chapter Overview

32.2. Company A

32.2.1. Company Snapshot

32.2.2. Interview Transcript: President and Chief Executive Officer

32.3. Company B

32.3.1. Company Snapshot

32.3.2. Interview Transcript: Medical Director, Professor, Associate Professor

32.4. Company C

32.4.1. Company Snapshot

32.4.2. Interview Transcript: Director

32.5. Company D

32.5.1. Company Snapshot

32.5.2. Interview Transcript: Nephrologist, Nephrologist

32.6. Company E

32.6.1. Company Snapshot

32.6.2. Interview Transcript: Executive Director

32.7. Company F

32.7.1. Company Snapshot

32.7.2. Interview Transcript: Founder and Chief Executive Officer

32.8. Company G

32.8.1. Company Snapshot

32.8.2. Interview Transcript: Professor

32.9. Company H

32.9.1. Company Snapshot

32.9.2. Interview Transcript: President and Chief Executive Officer

32.10. Company I

32.10.1. Company Snapshot

32.10.2. Interview Transcript: Associate BD Director

+ 33. APPENDIX I: TABULATED DATA

+ 34. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 3.3 Market Dynamics: Example List of Parameters

Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Key Historical Events related to Rare Kidney Diseases

Figure 6.2 Factors Contributing to the Onset of Kidney Diseases

Figure 6.3 Examples of Rare Kidney Diseases

Figure 6.4 Challenges Related to Diagnosis and Treatment of Rare Kidney Diseases

Figure 6.5 Selection of Therapeutic Targets for Rare Kidney Diseases

Figure 6.6 Technological Advancements in the Rare Kidney Diseases Domain

Figure 7.1 Rare Kidney Disease Drugs / Therapies: Distribution by Stage of Development

Figure 7.2 Rare Kidney Disease Drugs / Therapies: Distribution by Target Indication

Figure 7.3 Rare Kidney Disease Drugs / Therapies: Distribution by Route of Administration

Figure 7.4 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Molecule

Figure 7.5 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Biologic

Figure 7.6 Rare Kidney Disease Drugs / Therapies: Distribution by Dosing Frequency

Figure 7.7 Rare Kidney Disease Drugs / Therapies: Distribution by Target Patient Population

Figure 7.8 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Therapy

Figure 7.9 Rare Kidney Disease Drug / Therapy Developers: Distribution by Year of Establishment

Figure 7.10 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size

Figure 7.11 Rare Kidney Disease Drug / Therapy Developers: Distribution by Location of Headquarters

Figure 7.12 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size and Location of Headquarters

Figure 7.13 Most Active Players: Analysis by Number of Drugs / Therapies Developed

Figure 8.1 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Company Size

Figure 8.2 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Stage of Development

Figure 8.3 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Type of Molecule

Figure 8.4 Competitiveness Analysis of Players based in North America

Figure 8.5 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Company Size

Figure 8.6 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Type of Molecule

Figure 8.7 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Route of Administration

Figure 8.8 Competitiveness Analysis of Players based in Europe

Figure 8.9 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Company Size

Figure 8.10 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Stage of Development

Figure 8.11 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Type of Molecule

Figure 8.12 Competitiveness Analysis of Players based in Asia-Pacific and Rest of the World

Figure 9.1 AstraZeneca (Parent company of Alexion Pharmaceuticals): Annual Revenues, Since FY 2022 (USD Billion)

Figure 9.2 Vertex Pharmaceuticals: Annual Revenues, Since FY 2022 (USD Billion)

Figure 9.3 Novartis: Annual Revenues, Since FY 2022 (USD Billion)

Figure 9.4 Roche: Annual Revenues, Since FY 2022 (CHF Billion)

Figure 9.5 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, Since FY 2022 (RMB Billion)

Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership

Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Figure 10.4 Partnerships and Collaborations: Distribution by Target Indication

Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner

Figure 10.6 Most Active Players: Distribution by Number of Partnerships

Figure 10.7 Partnerships and Collaborations: Local and International Deals

Figure 10.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals

Figure 10.9 Partnerships and Collaborations: Recent Examples

Figure 11.1 Funding and Investments: Funding Lifecycle Analysis

Figure 11.2 Funding and Investments: Distribution of Funding Instances by Year of Funding

Figure 11.3 Funding and Investments: Distribution of Funding Instances by Type of Funding

Figure 11.4 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding

Figure 11.5 Funding and Investments: Distribution of Amount Invested by Year of Funding

Figure 11.6 Funding and Investments: Distribution of Amount Invested by Type of Funding

Figure 11.7 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding

Figure 11.8 Funding and Investments: Distribution of Funding Instances by Target Indication

Figure 11.9 Funding and Investments: Distribution of Funding Instances by Geography (Region)

Figure 11.10 Funding and Investments: Distribution of Funding Instances by Geography (Country)

Figure 11.11 Most Active Players: Distribution by Number of Instances

Figure 11.12 Most Active Players: Distribution by Amount Invested

Figure 11.13 Leading Investors: Distribution by Number of Funding Instances

Figure 11.14 Funding and Investments: Summary

Figure 12.1 Clinical Trial Analysis: Distribution by Trial Registration Year

Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status

Figure 12.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled

Figure 12.5 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled

Figure 12.6 Clinical Trial Analysis: Distribution by Trial Phase

Figure 12.7 Clinical Trial Analysis: Distribution by Patients Enrolled and Trial Phase

Figure 12.8 Clinical Trial Analysis: Distribution by Study Design

Figure 12.9 Clinical Trial Analysis: Distribution by Type of Sponsor

Figure 12.10 Clinical Trial Analysis: Distribution by Gender

Figure 12.11 Most Active Industry Players: Distribution by Number of Trials

Figure 12.12 Most Active Non-Industry Players: Distribution by Number of Trials

Figure 12.13 Distribution by Trial Status, Trial Phase and Geography

Figure 12.14 Distribution of Clinical Trials by Trial Status and Geography

Figure 12.15 Distribution of Patients Enrolled by Trial Status and Geography

Figure 12.16 Geographical Distribution of Trials and Number of Patients Enrolled

Figure 12.17 Clinical Trials in North America: Key Insights

Figure 12.18 Clinical Trials in Europe: Key Insights

Figure 12.19 Clinical Trials in Asia-Pacific: Key Insights

Figure 12.20 Clinical Trials in Rest of the World: Key Insights

Figure 13.1 Phase III Drugs / Therapies Targeting Rare Kidney Diseases

Figure 14.1 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of KOL

Figure 14.2 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Qualification

Figure 14.3 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of Organization

Figure 14.4 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Target Indication

Figure 14.5 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Geographical Location

Figure 14.6 Most Prominent Key Opinion Leaders

Figure 14.7 Benchmarking: Roots Analysis’ Assessment vs Third Party Scores

Figure 15.1 Benefits Offered by Kidney Care Companies

Figure 17.1 Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040 (USD Billion)

Figure 17.2 Global Rare Kidney Disease Market, Historical Trends (since 2023) and Forecasted Estimates, till 2040: Conservative Scenario (USD Billion)

Figure 17.3 Global Rare Kidney Disease Market, Historical Trends (since 2023) and Forecasted Estimates, till 2040: Optimistic Scenario (USD Billion)

Figure 18.1 Rare Kidney Disease Market: Distribution by Target Indication

Figure 18.2 Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.3 Rare Kidney Disease Market for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.4 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.5 Rare Kidney Disease Market for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.6 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040 (USD Million)

Figure 18.7 Rare Kidney Disease Market for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.8 Rare Kidney Disease Market for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.9 Rare Kidney Disease Market for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.10 Rare Kidney Disease Market for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 18.11 Rare Kidney Disease Market for Membranous Nephropathy: Forecasted Estimates, till 2040 (USD Million)

Figure 18.12 Rare Kidney Disease Market for Nephrotic Syndrome: Forecasted Estimates, till 2040 (USD Million)

Figure 19.1 Rare Kidney Disease Market: Distribution by Type of Molecule

Figure 19.2 Rare Kidney Disease Market for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 19.3 Rare Kidney Disease Market for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 20.1 Rare Kidney Disease Market: Distribution by Type of Biologic

Figure 20.2 Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 20.3 Rare Kidney Disease Market for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 20.4 Rare Kidney Disease Market for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040 (USD Million)

Figure 20.5 Rare Kidney Disease Market for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 20.6 Rare Kidney Disease Market for Cell and Gene Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 21.1 Rare Kidney Disease Market: Distribution by Route of Administration

Figure 21.2 Rare Kidney Disease Market for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 21.3 Rare Kidney Disease Market for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 21.4 Rare Kidney Disease Market for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 22.1 Rare Kidney Disease Market: Distribution by Type of Therapy

Figure 22.2 Rare Kidney Disease Market for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 22.3 Rare Kidney Disease Market for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040 (USD Million)

Figure 23.1 Rare Kidney Disease Market: Distribution by Geographical Regions

Figure 23.2 Rare Kidney Disease Market in North America: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.3 Rare Kidney Disease Market in the United States: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.4 Rare Kidney Disease Market in Canada: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.5 Rare Kidney Disease Market in Europe: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.6 Rare Kidney Disease Market in Germany: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.7 Rare Kidney Disease Market in United Kingdom: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.8 Rare Kidney Disease Market in France: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.9 Rare Kidney Disease Market in Spain: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.10 Rare Kidney Disease Market in Italy: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.11 Rare Kidney Disease Market in Rest of Europe: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.12 Rare Kidney Disease Market in Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.13 Rare Kidney Disease Market in China: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.14 Rare Kidney Disease Market in Japan: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.15 Rare Kidney Disease Market in Australia: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.16 Rare Kidney Disease Market in India: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.17 Rare Kidney Disease Market in South Korea: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.18 Rare Kidney Disease Market in Rest of Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.19 Rare Kidney Disease Market in Latin America: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.20 Rare Kidney Disease Market in Brazil: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.21 Rare Kidney Disease Market in Mexico: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.22 Rare Kidney Disease Market in Argentina: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.23 Rare Kidney Disease Market in Middle East and Africa: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.24 Rare Kidney Disease Market in Saudi Arabia: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.25 Rare Kidney Disease Market in Israel: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.26 Rare Kidney Disease Market in United Arab Emirates: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 23.27 Rare Kidney Disease Market in Egypt: Historical Trends (since 2023) and Forecasted Estimates, till 2040

Figure 24.1 ULTOMIRIS® (Atypical Hemolytic Uremic Syndrome): Sales Forecast

Figure 24.2 Tarpeyo® (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.3 Galafold (Fabry Disease): Sales Forecast

Figure 24.4 FILSPARI® (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.5 Benlysta® (Lupus Nephritis): Sales Forecast

Figure 24.6 Fabhalta (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.7 LUPKYNIS® (Lupus Nephritis): Sales Forecast

Figure 24.8 FILSPARI® (Focal Segmental Glomerulosclerosis): Sales Forecast

Figure 24.9 Voyxact (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.10 Elfabrio® (Fabry Disease): Sales Forecast

Figure 24.11 Vanrafia (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.12 Obinutuzumab (Lupus Nephritis): Sales Forecast

Figure 24.13 Fabhalta (Complement 3 Glomerulopathy): Sales Forecast

Figure 24.14 TERLIVAZ (Hepatorenal Syndrome): Sales Forecast

Figure 24.15 EMPAVELI (Complement 3 Glomerulopathy): Sales Forecast

Figure 24.16 EMPAVELI (Immune Complex-Mediated Membranoproliferative Glomerulonephritis): Sales Forecast

Figure 24.17 Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.18 Sibnayal® (Distal Renal Tubular Acidosis): Sales Forecast

Figure 24.19 Sefaxersen (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.20 Atacicept (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.21 Obinutuzumab (Membranous Nephropathy): Sales Forecast

Figure 24.22 Obinutuzumab (Nephrotic Syndrome): Sales Forecast

Figure 24.23 Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast

Figure 24.24 INM004 (Atypical Hemolytic Uremic Syndrome): Sales Forecast

Figure 24.25 Venglustat (Fabry Disease): Sales Forecast

Figure 24.26 Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.27 Fabhalta (Atypical Hemolytic Uremic Syndrome): Sales Forecast

Figure 24.28 ULTOMIRIS (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.29 SNP-ACTH (Membranous Nephropathy): Sales Forecast

Figure 24.30 Povetacicept (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.31 Mezagitamab (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.32 Ianalumab (Lupus Nephritis): Sales Forecast

Figure 24.33 Saphnelo (Lupus Nephritis): Sales Forecast

Figure 24.34 Felzartamab (Immunoglobulin A Nephropathy): Sales Forecast

Figure 24.35 Felzartamab (Membranous Nephropathy): Sales Forecast

Figure 24.36 Irbesartan (Focal Segmental Glomerulosclerosis): Sales Forecast

Figure 24.37 Lucerastat (Fabry Disease): Sales Forecast

Figure 24.38 Fabhalta (Immune Complex-Mediated Membranoproliferative Glomerulonephritis): Sales Forecast

Figure 24.39 BI 764198 (Focal Segmental Glomerulosclerosis): Sales Forecast

Figure 25.1 Rare Kidney Disease Market, Distribution by Leading Players, 2026 (USD Billion)

Figure 25.2 Rare Kidney Disease Market, Distribution by Leading Players, 2040 (USD Billion)

+ List of Tables

Table 7.1 List of Rare Kidney Disease Drugs / Therapy Programs

Table 7.2 List of Rare Kidney Disease Drug Developers

Table 9.1 SanegeneBio: Drug Portfolio

Table 9.2 Alexion Pharmaceuticals: Drug Portfolio

Table 9.3 Vertex Pharmaceuticals: Drug Portfolio

Table 9.4 Novartis: Drug Portfolio

Table 9.5 Roche: Drug Portfolio

Table 9.6 Jiangsu Hengrui Pharmaceuticals: Drug Portfolio

Table 9.7 Advicenne: Drug Portfolio

Table 9.8 Amgen: Drug Portfolio

Table 9.9 Asahi Kasei: Drug Portfolio

Table 9.10 Biogen: Drug Portfolio

Table 9.11 Boehringer Ingelheim: Drug Portfolio

Table 9.12 Calliditas Therapeutics: Drug Portfolio

Table 9.13 NovelMed: Drug Portfolio

Table 9.14 Travere Therapeutics: Drug Portfolio

Table 9.15 Vera Therapeutics: Drug Portfolio

Table 9.16 ZyVersa Therapeutics: Drug Portfolio

Table 10.1 Rare Kidney Disease Drugs / Therapies: List of Partnerships and Collaborations, since 2019

Table 11.1 Rare Kidney Disease Drugs / Therapies: List of Funding and Investments, since 2019

Table 12.1 Rare Kidney Disease Drugs / Therapies: List of Clinical Trials, 2020-2026

Table 14.1 Rare Kidney Disease Drugs / Therapies: List of Key Opinion Leaders

Table 15.1 Rare Kidney Disease Market: List of Kidney Care Companies

Table 17.1 Rare Kidney Disease Therapies: List of Forecasted Drugs

Table 28.1 Rare Kidney Disease Drugs / Therapies: Distribution by Stage of Development

Table 28.2 Rare Kidney Disease Drugs / Therapies: Distribution by Target Indication

Table 28.3 Rare Kidney Disease Drugs / Therapies: Distribution by Route of Administration

Table 28.4 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Molecule

Table 28.5 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Biologic

Table 28.6 Rare Kidney Disease Drugs / Therapies: Distribution by Dosing Frequency

Table 28.7 Rare Kidney Disease Drugs / Therapies: Distribution by Target Patient Population

Table 28.8 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Therapy

Table 28.9 Rare Kidney Disease Drug / Therapy Developers: Distribution by Year of Establishment

Table 28.10 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size

Table 28.11 Rare Kidney Disease Drug / Therapy Developers: Distribution by Location of Headquarters

Table 28.12 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size and Location of Headquarters

Table 28.13 Most Active Players: Analysis by Number of Drugs / Therapies Developed

Table 28.14 Rare Kidney Disease Drug / Therapy Developers based in North America: Distribution by Company Size

Table 28.15 Rare Kidney Disease Drug / Therapy Developers based in North America: Distribution by Stage of Development

Table 28.16 Rare Kidney Disease Drug / Therapy Developers based in North America: Distribution by Type of Molecule

Table 28.17 Rare Kidney Disease Drug / Therapy Developers based in Europe: Distribution by Company Size

Table 28.18 Rare Kidney Disease Drug / Therapy Developers based in Europe: Distribution by Type of Molecule

Table 28.19 Rare Kidney Disease Drug / Therapy Developers based in Europe: Distribution by Route of Administration

Table 28.20 Rare Kidney Disease Drug / Therapy Developers based in Asia-Pacific and Rest of the World: Distribution by Company Size

Table 28.21 Rare Kidney Disease Drug / Therapy Developers based in Asia-Pacific and Rest of the World: Distribution by Stage of Development

Table 28.22 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Type of Molecule

Table 28.23 AstraZeneca (Parent company of Alexion Pharmaceuticals): Annual Revenues, Since FY 2022 (USD Billion)

Table 28.24 Vertex Pharmaceuticals: Annual Revenues, Since FY 2022 (USD Billion)

Table 28.25 Novartis: Annual Revenues, Since FY 2022 (USD Billion)

Table 28.26 Roche: Annual Revenues, Since FY 2022 (CHF Billion)

Table 28.27 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, Since FY 2022 (RMB Billion)

Table 28.28 Partnerships and Collaborations: Distribution by Year of Partnership

Table 28.29 Partnerships and Collaborations: Distribution by Type of Partnership

Table 28.30 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 28.31 Partnerships and Collaborations: Distribution by Target Indication

Table 28.32 Partnerships and Collaborations: Distribution by Type of Partner

Table 28.33 Most Active Players: Distribution by Number of Partnerships

Table 28.34 Partnerships and Collaborations: Local and International Deals

Table 28.35 Partnerships and Collaborations: Intercontinental and Intracontinental Deals

Table 28.36 Funding and Investments: Distribution of Funding Instances by Year of Funding

Table 28.37 Funding and Investments: Distribution of Funding Instances by Type of Funding

Table 28.38 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding

Table 28.39 Funding and Investments: Distribution of Amount Invested by Year of Funding

Table 28.40 Funding and Investments: Distribution of Amount Invested by Type of Funding

Table 28.41 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding

Table 28.42 Funding and Investments: Distribution of Funding Instances by Target Indication

Table 28.43 Funding and Investments: Distribution of Funding Instances by Geography (Region)

Table 28.44 Funding and Investments: Distribution of Funding Instances by Geography (Country)

Table 28.45 Most Active Players: Distribution by Number of Instances

Table 28.46 Most Active Players: Distribution by Amount Invested

Table 28.47 Leading Investors: Distribution by Number of Funding Instances

Table 28.48 Funding and Investments: Summary

Table 28.49 Clinical Trial Analysis: Distribution by Trial Registration Year

Table 28.50 Clinical Trial Analysis: Distribution by Trial Status

Table 28.51 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Table 28.52 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled

Table 28.53 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled

Table 28.54 Clinical Trial Analysis: Distribution by Trial Phase

Table 28.55 Clinical Trial Analysis: Distribution by Patients Enrolled and Trial Phase

Table 28.56 Clinical Trial Analysis: Distribution by Study Design

Table 28.57 Clinical Trial Analysis: Distribution by Type of Sponsor

Table 28.58 Clinical Trial Analysis: Distribution by Gender

Table 28.59 Most Active Industry Players: Distribution by Number of Trials

Table 28.60 Most Active Non-Industry Players: Distribution by Number of Trials

Table 28.61 Distribution by Trial Status, Trial Phase and Geography

Table 28.62 Distribution of Clinical Trials by Trial Status and Geography

Table 28.63 Distribution of Patients Enrolled by Trial Status and Geography

Table 28.64 Clinical Trials in North America: Key Insights

Table 28.65 Clinical Trials in Europe: Key Insights

Table 28.66 Clinical Trials in Asia-Pacific: Key Insights

Table 28.67 Clinical Trials in Rest of the World: Key Insights

Table 28.68 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of KOL

Table 28.69 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Qualification

Table 28.70 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of Organization

Table 28.71 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Target Indication

Table 28.72 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Geographical Location

Table 28.73 Benchmarking: Roots Analysis’ Assessment vs Third Party Scores

Table 28.74 Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040 (USD Billion)

Table 28.75 Global Rare Kidney Disease Market, Historical Trends (since 2023) and Forecasted Estimates, till 2040: Conservative Scenario (USD Billion)

Table 28.76 Global Rare Kidney Disease Market, Historical Trends (since 2023) and Forecasted Estimates, till 2040: Optimistic Scenario (USD Billion)

Table 28.77 Rare Kidney Disease Market: Distribution by Target Indication

Table 28.78 Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.79 Rare Kidney Disease Market for Lupus Nephritis: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.80 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.81 Rare Kidney Disease Market for Fabry Disease: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.82 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.83 Rare Kidney Disease Market for Complement 3 Glomerulopathy: Historical Trends (since 2025) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.84 Rare Kidney Disease Market for Hepatorenal Syndrome: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.85 Rare Kidney Disease Market for Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Historical Trends (since 2025) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.86 Rare Kidney Disease Market for Distal Renal Tubular Acidosis: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.87 Rare Kidney Disease Market for Membranous Nephropathy: Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.88 Rare Kidney Disease Market for Nephrotic Syndrome: Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.89 Rare Kidney Disease Market: Distribution by Type of Molecule

Table 28.90 Rare Kidney Disease Market for Small Molecules: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.91 Rare Kidney Disease Market for Biologics: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.92 Rare Kidney Disease Market: Distribution by Type of Biologic

Table 28.93 Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.94 Rare Kidney Disease Market for Enzymes: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.95 Rare Kidney Disease Market for Proteins / Peptides: Historical Trends (since 2025) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.96 Rare Kidney Disease Market for Hormones: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.97 Rare Kidney Disease Market for Cell and Gene Therapies: Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.98 Rare Kidney Disease Market: Distribution by Route of Administration

Table 28.99 Rare Kidney Disease Market for Oral Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.100 Rare Kidney Disease Market for Intravenous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.101 Rare Kidney Disease Market for Subcutaneous Route: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.102 Rare Kidney Disease Market: Distribution by Type of Therapy

Table 28.103 Rare Kidney Disease Market for Monotherapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.104 Rare Kidney Disease Market for Combination Therapies: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.105 Rare Kidney Disease Market: Distribution by Geographical Regions

Table 28.106 Rare Kidney Disease Market in North America: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.107 Rare Kidney Disease Market in the United States: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.108 Rare Kidney Disease Market in Canada: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.109 Rare Kidney Disease Market in Europe: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.110 Rare Kidney Disease Market in Germany: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.111 Rare Kidney Disease Market in United Kingdom: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.112 Rare Kidney Disease Market in France: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.113 Rare Kidney Disease Market in Spain: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.114 Rare Kidney Disease Market in Italy: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.115 Rare Kidney Disease Market in Rest of Europe: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.116 Rare Kidney Disease Market in Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.117 Rare Kidney Disease Market in China: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.118 Rare Kidney Disease Market in Japan: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.119 Rare Kidney Disease Market in Australia: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.120 Rare Kidney Disease Market in India: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.121 Rare Kidney Disease Market in South Korea: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.122 Rare Kidney Disease Market in Rest of Asia-Pacific: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.123 Rare Kidney Disease Market in Latin America: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.124 Rare Kidney Disease Market in Brazil: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.125 Rare Kidney Disease Market in Mexico: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.126 Rare Kidney Disease Market in Argentina: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.127 Rare Kidney Disease Market in Middle East and Africa: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.128 Rare Kidney Disease Market in Saudi Arabia: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.129 Rare Kidney Disease Market in Israel: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.130 Rare Kidney Disease Market in United Arab Emirates: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.131 Rare Kidney Disease Market in Egypt: Historical Trends (since 2023) and Forecasted Estimates, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.132 ULTOMIRIS® (Atypical Hemolytic Uremic Syndrome): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.133 Tarpeyo® (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.134 Galafold (Fabry Disease): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.135 FILSPARI® (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.136 Benlysta® (Lupus Nephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.137 Fabhalta (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.138 LUPKYNIS® (Lupus Nephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.139 FILSPARI® (Focal Segmental Glomerulosclerosis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.140 Voyxact (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.141 Elfabrio® (Fabry Disease): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.142 Vanrafia (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.143 Obinutuzumab (Lupus Nephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.144 Fabhalta (Complement 3 Glomerulopathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.145 TERLIVAZ (Hepatorenal Syndrome): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.146 EMPAVELI (Complement 3 Glomerulopathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.147 EMPAVELI (Immune Complex-Mediated Membranoproliferative Glomerulonephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.148 Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.149 Sibnayal® (Distal Renal Tubular Acidosis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.150 Sefaxersen (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.151 Atacicept (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.152 Obinutuzumab (Membranous Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.153 Obinutuzumab (Nephrotic Syndrome): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.154 Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.155 INM004 (Atypical Hemolytic Uremic Syndrome): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.156 Venglustat (Fabry Disease): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.157 Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.158 Fabhalta (Atypical Hemolytic Uremic Syndrome): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.159 ULTOMIRIS (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.160 SNP-ACTH (Membranous Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.161 Povetacicept (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.162 Mezagitamab (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.163 Ianalumab (Lupus Nephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.164 Saphnelo (Lupus Nephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.165 Felzartamab (Immunoglobulin A Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.166 Felzartamab (Membranous Nephropathy): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.167 Irbesartan (Focal Segmental Glomerulosclerosis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.168 Lucerastat (Fabry Disease): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.169 Fabhalta (Immune Complex-Mediated Membranoproliferative Glomerulonephritis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.170 BI 764198 (Focal Segmental Glomerulosclerosis): Sales Forecast, till 2040, Conservative, Base and Optimistic Scenario (USD Million)

Table 28.171 Rare Kidney Disease Market, Distribution by Leading Players, 2026 (USD Billion)

Table 28.172 Rare Kidney Disease Market, Distribution by Leading Players, 2040 (USD Billion)

Rare Kidney Diseases Market